Destiny Pharma has an active programme of collaborative research investigating respiratory, dermal, oral and ocular infections including those associated with biofilms. These projects are mostly academic, commercial and collaborations funded through non-dilutive funding.
XF drugs have demonstrated efficacy in preclinical models of biofilm infection and Destiny Pharma has multiple active collaborations in this space:
Research collaboration with Aston University investigating novel compounds from the XF drug platform and their potential to prevent, control and eradicate dangerous bacteria in biofilms.
The National Biofilms Innovation Centre (NBIC) funded a research collaboration with Southampton University examining the utility of the XF drug platform for prevention, control, and eradication if chronic clinical infections with underlying biofilm involvement, such as those in diabetic foot ulcers and cystic fibrosis.
The Global AMR Innovation Fund (GAMRIF) made an award to Destiny Pharma in 2019 as part of the UK-China AMR programme. This long-term project collaborating with Cardiff University and Tianjin Medical University investigates the potential of the XF drug platform for the treatment of dermal and ocular infections and also supports the development of novel dermal and ophthalmic formulations for clinical use.
Further NBIC funded collaborations have been awarded in partnership with Sheffield University and Cardiff University to establish the potential of the XF drug platform as novel treatments for drug-resistant ocular infections and oral fungal infections.
Additional ongoing research projects include a collaboration with the Cystic Fibrosis Foundation and also research into Oral Mucositis.